Aarhus University Hospital — Sponsor Intelligence | 18 EU Trials

Filter these 18 trials by condition, phase, country and more.

Open in Search →

18 Registered trials

11 Recruiting

7 Completed trials

3 Countries active

35 Unique IMPs

100% Results reported

Phase II

Phase III/IV

Phase IV

Phase III: 1 Phase II/III: 1 Phase II: 7 Phase III/IV: 2 Phase IV: 7

Oversight events:

1 serious breach 2 corrective measures across 2 trials

View oversight register →

100%

7 of 7 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Type 2 diabetes mellitus 2 Cardiac arrest 1 Rheumatoid arthritis 1 Interstitial lung disease 1 Chronic kidney disease 1 Vulvovaginal discomfort 1

Top IMPs

SEMAGLUTIDE 2 SODIUM CHLORIDE 2 ZOLEDRONIC ACID 2 ACETYLSALICYLIC ACID 1 ALTEPLASE 1 ATENOLOL 1 B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2019 - LIKE VIRUS (B/WASHINGTON/02/2019, WILD TYPE), A/VICTORIA/2570/2019 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/2570/2019, IVR-215), INFLUENZA A VIRUS, A/CAMBODIA/E0826360/2020 (H3N2) - LIKE STRAIN (A/TASMANIA/503/2020, IVR-221), INACTIVATED 1 BCG (BACILLUS CALMETTE-GUÉRIN) BACTERIA 1 DAPAGLIFLOZIN 1 EPTINEZUMAB 1 FINERENONE 1 FREMANEZUMAB 1

All trials

18 total

Is there an effect of local vaginal estrogen treatment on the hemostatic parameters in postmenopausal women? Recruiting

2024-519539-41-00 Phase IV 1 country
Effect of Treatment with Finerenone on Cardio-Renal Target Organ Damage in Patients with Type 2 Diabetes – A Randomized Trial Recruiting

2023-504446-58-00 Phase IV 1 country FINERENONE
Palliation of Dyspnea and Cough using Morphine in patients with Fibrotic Interstitial Lung Disease Recruiting

2023-503700-81-00 Phase IV 1 country MORPHINE SULFATE
Fremanezumab for pain in Complex Regional Pain Syndrome Recruiting

2022-503167-15-00 Phase II 1 country FREMANEZUMAB
The OPTIMIST study Recruiting

2023-505940-20-00 Phase III/IV 1 country ROMOSOZUMAB; ZOLEDRONIC ACID
Infliximab for non-Crohn Anal Fistulas Recruiting

2022-502263-38-00 Phase II 1 country
Does peri-operative treatment with Tranexamic Acid reduce the early relapse rate for patients with melanoma; a randomised controlled trial Recruiting

2022-502633-26-00 Phase III 1 country TRANEXAMIC ACID
Treatment with zoledronate subsequent to denosumab in osteoporosis 2 Recruiting

2022-502621-17-00 Phase III/IV 1 country ZOLEDRONIC ACID
Acute Subcutaneous Semaglutide in Acute Ischemic Stroke (ASSET Trial) Recruiting

2022-501072-25-02 Phase II 1 country ACETYLSALICYLIC ACID; ALTEPLASE; LOPERAMIDE HYDROCHLORIDE; ONDANSETRON; SEMAGLUT…
INVITED trial Recruiting

2022-500906-17-01 Phase II 1 country B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/WASHINGTON/02/2…
Screening and intervention for subclinical coronary artery disease in patients with type 2 diabetes: THE STENO INTEN-CT STUDY Recruiting

2022-500143-21-01 Phase IV 1 country ATENOLOL; DAPAGLIFLOZIN; GLYCERYL TRINITRATE; IOMEPROL; IVABRADINE; METOPROLOL T…
CAT-Trial: CGRP monoclonal Antibody for Treatment of painful diabetic neuropathy: a double-blind, multicenter, placebo-controlled, internati… Ended

2022-500338-27-00 Phase II 1 country EPTINEZUMAB; SODIUM CHLORIDE
Investigation of tissue-resident memory T-cells and disease MEMory in psoriasis during GUSelkumab treatment. The GUSMEM study. Ended

2023-503776-25-00 Phase IV 1 country GUSELKUMAB
Bicarbonate for the treatment of cardiac arrest Ended

2022-501304-10-00 Phase IV 1 country SODIUM CHLORIDE; SODIUM HYDROGEN CARBONATE
NORTH-REG Dwell-Time Study Ended

2023-505936-37-00 Phase IV 3 countries BCG (BACILLUS CALMETTE-GUÉRIN) BACTERIA
Thiamine Against Chronic Rheumatoid Arthritis Fatigue Ended

2022-500922-13-00 Phase II/III 1 country
Treatment with Xeljanz in a population of patients with cutaneous T cell lymphoma Ended

2022-500599-79-00 Phase II 1 country TOFACITINIB
Insulin Resistance and Statin Treatment in Renal Transplant Recipients and Patients with Chronic Kidney Disease Ended

2022-501068-16-00 Phase II 1 country PRAVASTATIN SODIUM

Showing 1–18 of 18 trials

← All sponsors A–Z